Cefadroxil: Difference between revisions
Annhuang04 (talk | contribs) |
Annhuang04 (talk | contribs) |
||
| Line 19: | Line 19: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B (no evidence of harm) | ||
*Lactation: | *Lactation: safe (no risk/minimal risk) | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult | ||
***GFR 25-50: 1g x1, then 500mg q12h | |||
***GFR 10-25: 1g x1 then 500mg q24h | |||
***GFR < 10: 1g x1, then 500mg q36h | |||
***HD: give 0.5-1g supplement | |||
***PD: 500mg q24h | |||
**Pediatric | **Pediatric | ||
***GFR 10-25: give q24h | |||
***GFR < 10: give q36h | |||
***HD: give supplement | |||
***PD: no supplement | |||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult: not defined | ||
**Pediatric | **Pediatric: not defined | ||
==Contraindications== | ==Contraindications== | ||
Revision as of 01:04, 3 September 2015
General
- Type: First generation cephalosporin
- Dosage Forms: 500, 1000; 250, 500/5ml susp
- Common Trade Names: Duricef
Adult Dosing
- infections, bacteria
- 1-2g/day PO divided q12-24h
- pharyngitis/tonsillitis, streptococcal
- 1g PO divided q12-24h x 10days
Pediatric Dosing
- infections, bacterial
- 30mg/kg/day PO divided q12-24h max 2g/day
- paryngitis/tonsillitis, streptococcal
- 30 mg/kg/day PO divided q12-24h x 10days, max 1g/day
Special Populations
- Pregnancy Rating: B (no evidence of harm)
- Lactation: safe (no risk/minimal risk)
- Renal Dosing
- Adult
- GFR 25-50: 1g x1, then 500mg q12h
- GFR 10-25: 1g x1 then 500mg q24h
- GFR < 10: 1g x1, then 500mg q36h
- HD: give 0.5-1g supplement
- PD: 500mg q24h
- Pediatric
- GFR 10-25: give q24h
- GFR < 10: give q36h
- HD: give supplement
- PD: no supplement
- Adult
- Hepatic Dosing
- Adult: not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
Source
- ↑ Sanford Guide to Antimicrobial Therapy 2014
